Duración del tratamiento antiagregante en el síndrome coronario agudo

At present, dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor is the treatment of choice for patients with acute coronary syndrome and for those undergoing percutaneous coronary interventions. Although the general recommendation is that treatment should be maintained for 12 months after the occurrence of an acute coronary syndrome and after implantation of a drug-eluting stent, the optimum treatment duration is still unclear in a number of clinical settings. The aim of this article was to provide an overview what is currently known about the use of different durations of dual antiplatelet therapy in acute coronary syndrome by considering the evidence available from studies in patients with acute coronary syndrome and in those undergoing percutaneous coronary interventions involving stent implantation.